Acrivon Therapeutics Inc
ACRV1.295USD
+0.035+2.78%
Horário de mercado （ET）Cotações atrasadas em 15 min
40.60MValor de mercado
PerdaP/L TTM
Mais detalhes de Acrivon Therapeutics Inc Empresa
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Informações da empresa
Código da empresaACRV
Nome da EmpresaAcrivon Therapeutics Inc
Data de listagemNov 15, 2022
CEODr. Peter Blume-Jensen, M.D., Ph.D.
Número de funcionários75
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 15
Endereço480 Arsenal Way, Suite 100
CidadeWATERTOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02472
Telefone16172078979
Sitehttps://acrivon.com/
Código da empresaACRV
Data de listagemNov 15, 2022
CEODr. Peter Blume-Jensen, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.21M
-3.49%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
66.53K
-0.91%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
16.09K
-2.44%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mrs. Mary-Alice Miller, J.D.
Mrs. Mary-Alice Miller, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
--
-100.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.21M
-3.49%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
66.53K
-0.91%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
16.09K
-2.44%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 1 de ago
Atualizado em: sex, 1 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RA Capital Management, LP
26.60%
Chione, Ltd.
12.27%
Blume-Jensen (Peter)
7.04%
Sands Capital Ventures LLC
6.77%
Citadel Advisors LLC
6.05%
Other
41.28%
Investidores
Investidores
Proporção
RA Capital Management, LP
26.60%
Chione, Ltd.
12.27%
Blume-Jensen (Peter)
7.04%
Sands Capital Ventures LLC
6.77%
Citadel Advisors LLC
6.05%
Other
41.28%
Tipos de investidores
Investidores
Proporção
Venture Capital
26.60%
Hedge Fund
13.15%
Corporation
12.27%
Individual Investor
8.56%
Investment Advisor
7.97%
Investment Advisor/Hedge Fund
6.91%
Research Firm
0.36%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
24.12%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
142
23.71M
75.61%
-5.03M
2025Q1
146
29.35M
93.70%
-2.39M
2024Q4
141
30.19M
96.96%
-1.30M
2024Q3
129
30.21M
97.90%
-1.16M
2024Q2
124
30.86M
100.26%
+1.75M
2024Q1
110
20.99M
93.28%
+95.57K
2023Q4
96
21.08M
95.04%
+130.06K
2023Q3
91
21.13M
95.90%
+687.39K
2023Q2
85
20.62M
94.10%
+177.16K
2023Q1
71
22.16M
102.70%
+6.28M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
8.34M
26.6%
--
--
Mar 31, 2025
Chione, Ltd.
3.85M
12.27%
--
--
Jun 30, 2024
Blume-Jensen (Peter)
2.21M
7.04%
-79.67K
-3.49%
May 21, 2025
Sands Capital Ventures LLC
2.12M
6.77%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.90M
6.05%
-224.13K
-10.57%
Mar 31, 2025
Wellington Management Company, LLP
888.13K
2.83%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
844.91K
2.69%
-5.84K
-0.69%
Mar 31, 2025
The Vanguard Group, Inc.
674.79K
2.15%
+3.17K
+0.47%
Mar 31, 2025
Marshall Wace LLP
450.39K
1.44%
-147.40K
-24.66%
Mar 31, 2025
Acorn Capital Advisors, LLC
405.24K
1.29%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0%
Invesco Nasdaq Biotechnology ETF
Proporção0%
ProShares Ultra Nasdaq Biotechnology
Proporção0%
iShares Russell 2000 ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
iShares Biotechnology ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
Global X Russell 2000 ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
